2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
7
Breast Neoplasms
5
Ovarian Neoplasms
4
Pancreatic Neoplasms
3
Colorectal Neoplasms, Hereditary Nonpolyposis
3
Triple Negative Breast Neoplasms
2
Neoplastic Syndromes, Hereditary
2
Hereditary Breast and Ovarian Cancer Syndrome
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Urogenital Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Melanoma
1
Lymphoproliferative Disorders
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Fanconi Anemia, Complementation Group D1
1
Digestive System Neoplasms
1
Cytopenia
1
Congenital Bone Marrow Failure Syndromes
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Intraductal, Noninfiltrating
1
Cancer Risk Syndrome
1
Interventions
aldesleukin
43
Sunitinib
42
Cyclophosphamide
30
Nivolumab
29
pembrolizumab
27
Everolimus
27
Interferon-alpha
25
Bevacizumab
23
Sorafenib
22
Interleukin-2
20
fludarabine phosphate
19
Radiotherapy
18
Ipilimumab
18
Filgrastim
18
Axitinib
18
Gene Expression Profiling
16
Peripheral Blood Stem Cell Transplantation
15
Gemcitabine
15
cabozantinib
14
Radiosurgery
13
fludarabine
11
Doxorubicin
11
Carboplatin
11
Blood Specimen Collection
11
temsirolimus
10
atezolizumab
9
Immunohistochemistry
9
Etoposide
9
Chemotherapy, Adjuvant
9
sargramostim
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
Genetic Counseling
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled